Delivery Order SPE2DB22D3016-SPE2DB26FABL6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $1,100.49. This firm fixed-price delivery order, with an ultimate completion date of June 2, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made on...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $10,635.64. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery order is issued...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Naloxone HCl 4 mg nasal spray. The delivery order has a potential value of $2,039.75 and a completion date of February 16, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA that serves as the primary vehicle for the company to deliver pharmaceutical products and medical...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $10,222.79. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of July 30, 2025, supporting federal medical procurement needs. The contract is classified as a child order under a larger indefinite delivery contract vehicle and carries no set-aside designation, indicating open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on July 24, 2025, with a ceiling value of $1,583.26 and an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger indefinite delivery vehicle with DLA. This delivery order falls...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,061.22 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-dose units) on October 22, 2025, with completion scheduled for October 23, 2025. This firm fixed-price contract, awarded without set-aside restrictions, represents a competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on October 28, 2025, with a ceiling value of $2,708.48 and an ultimate completion date of October 29, 2025. This is a firm fixed price contract with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a small-value delivery order for a critical emergency medical product used in opioid overdose response,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) with a ceiling value of $1,092.00. This competitively awarded, firm fixed-price delivery order was issued on September 13, 2025, with an ultimate completion date of September 15, 2025. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Naloxone HCL 4 mg nasal spray in a quantity of 2 units. This contract is valued at $1,135.68 with a firm fixed price structure and an ultimate completion date of September 2, 2025. The award was competitively procured with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Naloxone HCl 4 mg nasal spray (2-count units) with a ceiling value of $12,536.81. This firm fixed-price delivery order is scheduled for completion by September 30, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FABL6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the procurement of Naloxone HCl 4 mg nasal spray (2-spray units) on November 5, 2025, with a ceiling value of $4,930.58. This is a firm fixed-price delivery order with an ultimate completion date of November 6, 2025. The award represents a competitive procurement with no set-aside designation, and performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this procurement leverages AmerisourceBergen's existing relationship with the DLA to fulfill pharmaceutical supply requirements for federal medical operations. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX) valued at $999,999,999.00 through December 2026, which serves as the comprehensive global pharmaceutical support vehicle enabling deliveries across multiple therapeutic domains. This delivery order for naloxone aligns with the Defense Logistics Agency's ongoing pharmaceutical supply chain operations and the company's established capability to fulfill federal medical procurement requirements through competitive awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 11/5/25 |